Peptide Lab HQ Research Guide
TB-500
A research-focused compound profile covering TB-500 identity, thymosin beta-4 fragment research, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | TB-500 |
|---|---|
| Compound Type | Synthetic thymosin beta-4 fragment |
| CAS Number | 885340-08-9 |
| PubChem CID | 62707662 |
| Amino Acid Length | 7 amino acids |
| Amino Acid Sequence | Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln |
| Short Sequence | Ac-LKKTETQ |
| Molecular Formula | C₃₈H₆₈N₁₀O₁₄ |
| Molecular Weight | Approximately 889.02 g/mol |
| Research Category | Actin regulation, cellular migration, angiogenesis, and tissue-response research |
| Appearance | White to off-white lyophilized powder |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
TB-500 is commonly discussed in controlled research models involving thymosin beta-4 fragment activity, actin regulation, cell migration, angiogenesis-related observations, and tissue-response pathways.
Actin Regulation Research
TB-500 is associated with thymosin beta-4 fragment research involving actin-binding regions and cytoskeletal regulation.
Cellular Migration Models
Used in research models exploring cell movement, endothelial migration, fibroblast behavior, and related cellular response pathways.
Angiogenesis Research
Discussed in research involving endothelial behavior, vascular-response signaling, tube formation, and angiogenesis-related observations.
Tissue-Response Studies
Commonly referenced in controlled research models involving tissue-response signaling and repair-associated biological pathways.
Extracellular Matrix Models
Relevant to research involving connective tissue signaling, extracellular matrix remodeling, and localized response documentation.
Preclinical Research Context
TB-500 discussion is primarily research-focused and should be framed around laboratory, preclinical, and educational reference use.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on compound form, salt form, purity, concentration, study model, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 2 mg TB-500 |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 1 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 1 mg/mL, 1 unit equals 0.01 mg / 10 mcg TB-500. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear. Do not shake!
- For higher-concentration preparations, verify that the material is fully dissolved before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | TB-500, commonly discussed in thymosin beta-4 / Tβ4 fragment research contexts | TB-500-style references are often discussed alongside thymosin beta-4 fragment, actin-binding domain, and tissue-response research. Supplier-specific identity should be verified by COA or batch record. |
| Actin / Cell-Migration Research | Model-dependent concentration and endpoint tracking | Thymosin beta-4-related research is commonly discussed in actin regulation, endothelial-cell migration, cellular motility, and cytoskeletal-response research contexts. |
| Angiogenesis Research Context | Experimental and model-dependent context | TB-500 / Tβ4-related references are commonly associated with angiogenesis-marker, endothelial-response, cell-migration, and vascular-remodeling research models. |
| Tissue-Response Research Context | Wound-healing and recovery-model context | Research discussions often involve tissue-repair, wound-response, re-epithelialization, collagen-deposition, inflammatory-marker, and recovery-model observations. |
| Inflammatory-Marker Research | Model-dependent inflammatory and tissue-protective context | Commonly discussed in inflammatory-marker, fibrosis-marker, apoptosis, tissue-protection, and cellular-stress-response research contexts. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references commonly describe TB-500 in microgram-to-milligram examples depending on the research model and preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, clinical-study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 2 mg | 2.0 mL | 1 mg/mL |
| 5 mg | 2.0 mL | 2.5 mg/mL |
| 10 mg | 2.0 mL | 5 mg/mL |
| 20 mg | 3.0 mL | 6.67 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 1 mg/mL | U-100 Unit Reference | Approx. References per 2 mg Vial |
|---|---|---|---|
| 0.1 mg / 100 mcg | 0.10 mL | 10 units | 20 |
| 0.25 mg / 250 mcg | 0.25 mL | 25 units | 8 |
| 0.5 mg / 500 mcg | 0.50 mL | 50 units | 4 |
| 1 mg / 1000 mcg | 1.00 mL | 100 units | 2 |
| 2 mg / 2000 mcg | 2.00 mL | 200 units | 1 |
| 5 mg / 5000 mcg | 5.00 mL | 500 units | 0.4 |
| 10 mg / 10000 mcg | 10.00 mL | 1000 units | 0.2 |
| 20 mg / 20000 mcg | 20.00 mL | 2000 units | 0.1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Low Conversion Reference | Calculation reference only | 0.1 mg reference amount | 10 units / 0.10 mL |
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.25 mg reference amount | 25 units / 0.25 mL |
| Low-to-Mid Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 50 units / 0.50 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 100 units / 1.00 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 200 units / 2.00 mL |
| Upper Conversion Example | Calculation reference only | 5 mg reference amount | 500 units / 5.00 mL |
| High Conversion Example | Calculation reference only | 10 mg reference amount | 1000 units / 10.00 mL |
| Preparation-Level Conversion Example | Calculation reference only | 20 mg reference amount | 2000 units / 20.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Migration Observation Window | 24–72 hours | May be used for cell-migration, actin-regulation, endothelial-response, angiogenesis-marker, or cellular-motility documentation depending on the model. |
| Acute Tissue-Response Window | Single session to several days | Used for short-term inflammatory-marker comparison, cellular-response tracking, migration-marker observation, or early pathway documentation depending on the research design. |
| Short Research Window | 1–4 weeks | May be used for early controlled observation involving tissue-response, connective-tissue, angiogenesis-marker, or recovery-model endpoints. |
| Standard Protocol-Style Window | 4–8 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 8–12 weeks or longer | Used when longer documentation is needed for tissue-response trends, inflammatory-marker comparison, angiogenesis context, or follow-up marker tracking. |
| Follow-Up / Washout | 2–8 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. TB-500 is commonly discussed in thymosin beta-4 / Tβ4 fragment, actin-binding, cell-migration, angiogenesis, inflammatory-marker, tissue-response, connective-tissue, and recovery-model research contexts. The selector above updates calculations for 2 mg, 5 mg, and 10 mg vial references reconstituted with 2.0 mL bacteriostatic water, and a 20 mg vial reference reconstituted with 3.0 mL bacteriostatic water. TB-500 supplier identity and sequence format should be verified against the COA, batch record, or formula record when available. Published study references, clinical-study contexts, and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
TB-500 is commonly discussed in research involving thymosin beta-4 fragment activity, actin regulation, cell migration, angiogenesis-related observations, endothelial behavior, and tissue-response pathways.
Study Limitations
TB-500 is primarily discussed in research and preclinical contexts. Research interpretation may vary based on compound form, purity, model type, concentration, and laboratory conditions.
Safety Considerations
Laboratory handling should include appropriate PPE, sterile technique, proper labeling, batch documentation, and qualified research procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.